Atopic Dermatitis

These data suggest that the choice of allergens for patch testing should remain the same among individuals with and without atopic dermatitis.

These data on systemic inflammatory biomarkers for patients with eczema may allow for more targeted treatments and for greater personalization of medicine for this skin condition.

A phase 2 trial shows tofacitinib improves autoimmune conditions in Down syndrome, with notable skin health benefits and a good safety profile.

Lindsay S. Ackerman, MD, FAAD, provides clinical insights on best practices for evaluating treatment response in patients with atopic dermatitis.

Lindsay S. Ackerman, MD, FAAD, and Jonathan Silverberg, MD, PhD, MPH, discuss how patient goals inform treatment decisions for patients with atopic dermatitis.

Identified proteins impacted by the presence of atopic dermatitis may provide clinicians a better understanding of how to treat it.

This study highlights the impact of dietary vitamin E intake on the inflammatory skin condition of atopic dermatitis, also known as eczema.

The results of this analysis can inform clinical decision-making conversations held between patients with eczema and their physicians.

In an interview, Raj Chovatiya, MD, PhD, highlights the effectiveness of lebrikizumab, providing stable improvements by week 52.

These data highlight the effects on eczema following treatment with dupilumab, tralokinumab, and lebrikizumab in terms of improvements in EASI, IGA, and other measures.

This analysis was conducted to evaluate the effect of pruritus on quality of life ratings among individuals with atopic dermatitis and psoriasis.

Experts on atopic dermatitis describe the burden of the disease and provide clinical insights on counseling patients who are experiencing sleep disturbances.

A panel of dermatologists discuss the heterogeneity of clinical presentations of atopic dermatitis and offer ways to reduce misdiagnosis.

This analysis compared drug survival rates of abrocitinib and dupilumab in the treatment of adults with eczema, with different benefits highlighted for both therapies.

Atopic dermatitis increases stress, depression, anxiety, and suicidal ideation, affecting patients' mental health, a recent study found.

Study finds 70% of atopic dermatitis patients using dupilumab continued for up to 5 years, but 23.8% discontinued primarily due to adverse events or ineffectiveness.

In this analysis, investigators highlighted the perceptions of individuals with HS and atopic dermatitis and assessed higher rates of stigmatization.

These findings were the result of an active-comparator study, highlighting the benefits of betamethasone versus tacrolimus among patients with eczema.

This research compared the efficacy among a cohort of individuals with obesity to the general population of adult patients with eczema.

Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.

This interview segment featured Silverberg discussing the AHEAD atopic dermatitis recommendations and their implications for clinicians and patients.

Silverberg discusses the new AHEAD recommendations for optimizing atopic dermatitis management, highlighting goals, disease severity assessments, and guidance for escalation.

In this Month in Review, the editorial team highlights major news covered in the field of dermatology, including FDA approvals, interviews, and new findings on drugs in the pipeline.

This announcement follows roflumilast’s July 9 approval for the once-daily treatment of adults and children with mild to moderate atopic dermatitis.

These findings support delgocitinib’s clinical benefit as a possible medication option for individuals with moderate to severe chronic hand eczema.

These new phase 3 findings from ARCADIA 1 and 2 highlight the effects of nemolizumab in combination with either topical corticosteroids or topical calcineurin inhibitors.

This meta-analysis was conducted to compare the efficacy and safety of lebrikizumab to other systemic treatments for patients with atopic dermatitis.

In this exclusive deep dive, a pair of leading dermatologists highlight the new data defining ruxotitinib cream, upadacitinib, and more agents from the revolutionary drug class.

Christopher Bunick, MD, PhD, offers advice for clinicians treating patients with atopic dermatitis.

An atopic dermatitis expert describes the results of the Level Up study, a phase 3b/4 trial comparing upadacitinib and dupilumab, which were recently presented at RAD 2024, focusing on the primary and secondary outcomes of the study.